Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This analysis reveals comparable 10-year mortality, valve durability, and hemodynamics between SAPIEN 3 transcatheter and surgical aortic valve replacement in intermediate-risk patients, underscoring TAVR’s durable benefit.
Three-year pooled data from the ALTERRA trials demonstrate that the Alterra Adaptive Prestent combined with the SAPIEN 3 THV is highly effective and safe for treating severe pulmonary regurgitation in patients with large right ventricular o
The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.